Influence of psychosocial risk factors on the course and prognosis of cardiovascular diseases
| Autor: | O. M. Drapkina, A. I. Fedin, O. A. Dorofeeva, V. E. Medvedev, E. N. Kareva, O. N. Dzhioeva, S. G. Kuklin, Е. Yu. Solovieva, D. I. Abdulganieva, Z. F. Kim, M. S. Grigorovich, I. I. Shaposhnik, N. А. Koryagina, S. B. Seredenin |
|---|---|
| Jazyk: | ruština |
| Rok vydání: | 2022 |
| Předmět: | |
| Zdroj: | Кардиоваскулярная терапия и профилактика, Vol 21, Iss 5 (2022) |
| Druh dokumentu: | article |
| ISSN: | 1728-8800 2619-0125 |
| DOI: | 10.15829/1728-8800-2022-3280 |
| Popis: | It has now been established that psychosocial risk factors significantly worsen the course of cardiovascular diseases (CVDs) and reduce patients’ adherence to treatment. Patients with CVDs are characterized by a high prevalence of anxiety comorbidities, which can reach 50-60%. The presence of concomitant anxiety disorders seriously worsens the prognosis of CVDs. The results of studies showed that anxiety increases the risk of fatal myocardial infarction and sudden death by 1,9 times and 4,5 times, respectively. Therefore, the correction of psychosocial factors, in particular anxiety symptoms, should be an important component of the treatment of patients with CVDs. The conducted studies show that the use of fabomotizole in patients with CVD and concomitant anxiety disorders reduces the anxiety manifestations. In addition, a pronounced improvement of somatic status is recorded, which is important for improving the course and prognosis of CVDs. The accumulated experience of fabomotizole use makes it possible to recommend it for the treatment of patients with anxiety and CVDs. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|